Results 111 to 120 of about 5,184 (154)

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain. [PDF]

J Med Virol
Azanza JR, González Del Castillo JM, Ferrando R, Molero JM, Soriano A, Peral C, de Lossada A, Bellmunt A, Garí C, Mugwagwa T, López-Gómez V.   +10 more
europepmc   +1 more source

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound". [PDF]

Viruses
Bhargava A, Szpunar S, Sharma M, Saravolatz L.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +7 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2023
  +9 more sources

Nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +2 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2022
  +4 more sources

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source

Nirmatrelvir+ritonavir

Reactions Weekly
  +5 more sources

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources